NAAG is calling on Congress to provide robust funding for the Legal Services Corporation which provides financial support for civil legal aid to low-income Americans. Letters were sent to House and Senate leadership.
We write, as the Attorneys General of our jurisdictions, to urge the Department of Education to take prompt action to satisfy its statutory mandate to discharge the student loans of veterans who are permanently and totally disabled or otherwise unemployable. As a nation, we have a moral obligation to assist those who have put their lives on the line to defend us.
Attorneys General Urge Senate to Support Veterans by Passing the Veteran Treatment Court Coordination Act
We urge the Senate to further support this important court program. H.R. 886 would establish a Veteran Treatment Court Program in the Department of Justice to provide grants and technical assistance to state, local and tribal courts that implement Veterans Treatment Courts. As Attorneys General, we strongly support this important program in our courts and encourage the continued support of the Congress for our nation’s veterans.
NAAG sent a letter to congressional leadership, urging them to pass the SAFE Banking Act. The bipartisan SAFE Banking Act would protect financial institutions that provide services to companies in the marijuana industry. Although the use of marijuana, both recreationally and medically, is legal in some states and territories, banks may still be held liable…
ASD impacts hundreds of thousands of Americans. Congress began addressing autism in 2000 with the first enactment of the bill. The 161 cosponsors of the current House and Senate bills and the 118+ bipartisan members of the Congressional Coalition for Autism Research and Education demonstrate its significance. The Autism CARES Act of 2019 will continue Congress’ ongoing mission to ensure that those living with ASD receive the necessary support and research. Therefore, we, the undersigned attorneys general, ask you to support and to enact the Autism Cares Act of 2019 before September 30, 2019.
This legislation is crucial to federal and state efforts to curb the opioid epidemic nationally and within each individual state. It is for these reasons that we commend Senators Portman and Manchin for their leadership in bringing forward this important legislation, and we urge you to take up and pass S. 2701 before the DEA’s temporary order expires.
Forty-three state and territory attorneys general submitted comments to the Federal Trade Commission (FTC) Hearings on Competition and Consumer Protection in the 21st Century.
Unfortunately, there are three significant barriers to treating opioid use disorder that we cannot change at the state level and that must be tackled at the federal level. We share these barriers below in the hope that we can work together to remove them and allow more providers to offer treatment for opioid use disorder and other substance use disorders.
The Draft Report should be revised to clearly state that there is no completely safe opioid dose, and that higher doses are particularly – and predictably – risks.
As the primary enforcers of our respective states’ consumer protection laws, we offer a unique perspective as to the new legalized market of certain cannabis and cannabis-derived compounds, including CBD products. We write to express our hope that the FDA continues to explore manufacturing, testing, and marketing best practices so that consumers are not at risk of misleading advertising or harm to their health from dangerous additives or undisclosed risks of use. Although products containing cannabis or cannabis-derived compounds may well offer real benefits to consumers, it is important that consumers have reliable risk and benefit information to make informed choices about initiating and continuing the use of these products. A crucial element of FDA regulation and oversight should be an on-going assessment of the potential risks or benefits of these products, particularly for specific populations such as pregnant women, adolescents and children, and the elderly. How these products interact with other dietary or pharmaceutical products should be included in this assessment. It is also important that companies not mislead consumers. Scientific and medical data from the FDA would assist in meaningful enforcement of advertising laws and regulations by the states.